Study of How Changes in NAD Metabolism Affect Kidney Health in Intensive Care Patients at High Risk of Acute Kidney Injury

What this Trial Is About

Acute renal failure ARF is a common and serious condition affecting many patients admitted to intensive care units, significantly impacting short-term survival and increasing risks related to chronic kidney disease and cardiovascular problems. This research explores the role of vitamin deficiency, particularly involving NAD metabolism, in the development of ARF in intensive care patients. The study aims to investigate whether changes in the metabolic pathway of NAD production, measured by the urinary QuinolinateTryptophan ratio on admission, are linked to the occurrence of ARF in this high-risk population. Participants admitted to intensive care for high-risk conditions such as shock, sepsis, cardiac arrest, and certain surgeries will be included. The study involves collecting a urine sample upon admission to assess kidney function and NAD metabolism. Follow-up includes a phone call on day 28 to gather information on recovery, hospital stay length, vital status, adverse events, and other treatments. This study does not involve drug treatment but focuses on diagnostic testing and monitoring. Throughout the study, participants will be closely observed for signs of acute renal insufficiency, with severity assessed within 12 hours and duration tracked over up to 28 days. Cardiovascular complications will also be monitored in the first week. The research team will collect data on patients health status and treatment during their hospital stay and follow them for 28 days to evaluate outcomes. This approach aims to improve understanding of factors influencing kidney injury in critically ill patients.

Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Care (NI-AKI)